Draft:Jean Abraham

Jean Abraham was born in Kerala, India, and moved to the United Kingdom when she was 2 years old. Her father was a GP in Liverpool.{{Cite web |url= https://doi.org/10.1136/bmj.l776 |title= BMJ article|doi= 10.1136/bmj.l776}} She was state educated in a non-selective comprehensive school in the Sefton Park area of Liverpool. She did a first degree in Pharmacology at Liverpool University, before qualifying in medicine in 1995, also from Liverpool University. She completed her residency in internal medicine at Addenbrookes hospital with MRCP before specialising in medical oncology. She has two younger sisters, both doctors.

Professor Abraham is Chief Investigator of the Cambridge Precision Breast Cancer Unit which has delivered the world's first integration of real time routine whole genome/RNA sequencing service into a standard clinical service.

All women and men with breast cancer treated at Addenbrooke’s Hospital, who consent to take part, undergo whole genome and exome sequencing. This data is integrated into NHS patient medical records, discussed by doctors at weekly genomic tumor board, and used to guide patient care decisions. By 2022 over 1000 patients had been through this program. In 2023 the US Department of Defense Office of Naval Research awarded a $6.5 million grant to Professor Abraham for the further development of this program. The Synergia-Breast Cancer Platform will integrate data from multiple sources (pathology, genomics, radiomics, microbiome, translational science) to create a single point of access for research, including machine learning and artifical intelligence{{Cite journal |title= Multi-omic machine learning predictor of breast cancer therapy response. Nature 2022|date= 2022|pmid= 34875674|last1= Sammut|first1= S. J.|last2= Crispin-Ortuzar|first2= M.|last3= Chin|first3= S. F.|last4= Provenzano|first4= E.|last5= Bardwell|first5= H. A.|last6= Ma|first6= W.|last7= Cope|first7= W.|last8= Dariush|first8= A.|last9= Dawson|first9= S. J.|last10= Abraham|first10= J. E.|last11= Dunn|first11= J.|last12= Hiller|first12= L.|last13= Thomas|first13= J.|last14= Cameron|first14= D. A.|author15= Bartlett JMS|last16= Hayward|first16= L.|last17= Pharoah|first17= P. D.|last18= Markowetz|first18= F.|last19= Rueda|first19= O. M.|last20= Earl|first20= H. M.|last21= Caldas|first21= C.|journal= Nature|volume= 601|issue= 7894|pages= 623–629|doi= 10.1038/s41586-021-04278-5|pmc= 8791834}}

Professor Abraham is Chief Investigator of eight national and regional clinical trials, most notably the Partner Trial{{Cite journal |title= The Partner trial of neoadjuvant Olaparib with chemotherapy in triple negative breast cancer. Nature 2024|date= 2024|pmid= 38588696|last1= Abraham|first1= J. E.|last2= Pinilla|first2= K.|last3= Dayimu|first3= A.|last4= Grybowicz|first4= L.|last5= Demiris|first5= N.|last6= Harvey|first6= C.|last7= Drewett|first7= L. M.|last8= Lucey|first8= R.|last9= Fulton|first9= A.|last10= Roberts|first10= A. N.|last11= Worley|first11= J. R.|last12= Chhabra|first12= A.|last13= Qian|first13= W.|last14= Vallier|first14= A. L.|last15= Hardy|first15= R. M.|last16= Chan|first16= S.|last17= Hickish|first17= T.|last18= Tripathi|first18= D.|last19= Venkitaraman|first19= R.|last20= Persic|first20= M.|last21= Aslam|first21= S.|last22= Glassman|first22= D.|last23= Raj|first23= S.|last24= Borley|first24= A.|last25= Braybrooke|first25= J. P.|last26= Sutherland|first26= S.|last27= Staples|first27= E.|last28= Scott|first28= L. C.|last29= Davies|first29= M.|last30= Palmer|first30= C. A.|journal= Nature|volume= 629|issue= 8014|pages= 1142–1148|doi= 10.1038/s41586-024-07384-2|pmc= 11136660|display-authors= 1}} which showed that there was no benefit from adding olaparib to standard chemotherapy for patients with triple negative breast cancer if they did not have a BRCA1 or BRCA2 mutation.

{{div col}}

• 2017 – Top 50 Female Movers and Shakers in UK BioHealth{{Cite web|url=https://www.mws-consulting.co.uk/wp-content/uploads//11/50-Movers-and-Shakers-in-BioBusiness-2017-WEB-final-311017.pdf|title=Top Movers and Shakers}}
• 2022 – NIHR Team Research East of England Excellence Award{{Cite web|url=https://www.integratedcancermedicine.org/news/cancer-research-excellence-awards/|title = East of England Excellence Award| date=19 December 2022 }}

{{reflist}}